skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Profile of teriparatide in the management of postmenopausal osteoporosis

Review

(2972) Views  (910) Full article downloads

Authors: Andrea Sikon, Pelin Batur

Published Date March 2010 Volume 2010:2 Pages 37 - 44
DOI: http://dx.doi.org/10.2147/IJWH.S4919

Andrea Sikon1, Pelin Batur2

1Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA; 2Cleveland Clinic Lerner COM, Cleveland Clinic Independence, Independence, OH, USA

Abstract: One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy: building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.

Keywords: osteoporosis, menopause, teriparatide








Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Periosteoplasty for covering gingival recessions: Clinical results
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis
Management of hypoactive sexual desire disorder in women: current and emerging therapies
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Is obesity in women protective against osteoporosis?
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Erratum